I'm negative about the DEP licensing mainly because Starpharma have touted for years that "commercial in confidence discussions with several potential partners" was occurring and yet here we are with not one single license deal for any of the 3 separate phase 2 trialed DEP drugs almost 5 years later. This is also why I question people who continually promote 'how great the science is' - you fit into that category and are like the other pumpers who can't seem to explain why no pharma company (big or small) throughout the globe has licensed it yet if the science is as good as you all claim ?
That said, I've been positive about Viraleze since I started using it 3+ years ago so I don't always dismiss the company as 'hopeless' like you state and of course have I spent >$4000 on importing Viraleze for our household under the TGA personal use scheme, which subsequently contributes to Starpharma's revenue and more than I can say for many on here that constantly big note themselves ?
If I didn't think Viraleze worked, I wouldn't pour that sort of money down the drain (our household occupants have never had COVID-19 that we are aware) and I attribute that to Viraleze but I am also now wondering why the TGA are taking so long to render an approval ? Given the multiple problems with regulators we have had throughout various countries (USA, UK, Australia etc) the common denominator is of course Starpharma so again one does wonder ?
GLTAH
- Forums
- ASX - By Stock
- SPL
- Majestic and Allan Gray doing some business today
Majestic and Allan Gray doing some business today, page-13
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.006(6.06%) |
Mkt cap ! $43.90M |
Open | High | Low | Value | Volume |
9.7¢ | 10.5¢ | 9.6¢ | $12.10K | 123.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1786 | 9.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 183631 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1786 | 0.098 |
1 | 75000 | 0.097 |
3 | 547556 | 0.096 |
1 | 824859 | 0.095 |
1 | 10000 | 0.093 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 183631 | 5 |
0.110 | 203882 | 6 |
0.115 | 59827 | 2 |
0.120 | 201197 | 5 |
0.125 | 30000 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online